510(k) device
PuraStat
3-D Matrix Europe SAS · Hemostatic Device For Endoscopic Gastrointestinal Use (QAU, Class II) · First FDA decision Oct 22, 2024, newest Jan 7, 2026Gastrointestinal bleeding
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
12
Naming "PuraStat"
MAUDE reports
3
Brand "PuraStat", since 2015
PubMed studies
83
Mentioning "PuraStat"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing PuraStat
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- PuraStat510(k)
K253924 · Decided Jan 7, 2026 · 30 days after receipt
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU) · General & Plastic Surgery
- PuraStat510(k)
K242250 · Decided Oct 22, 2024 · 83 days after receipt
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PuraStat", any status and sponsor, newest update first.
- RADA16 for Aquablation Day CaseCompleted
NYU Langone HealthAcademic, hospital or other
NCT06948331 · 24 participants · Start May 14, 2026 · Primary completion Sep 17, 2026
Device: PuraStat · For: Hematuria; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms
Sites: New York, New York
Endeavor HealthAcademic, hospital or other
NCT07789041 · 50 participants (planned) · Start Aug 12, 2025 · Primary completion Sep 1, 2026
Device: PuraStat hydrogel and the syringe · For: BPH (Benign Prostatic Hyperplasia); BPH With Symptomatic Lower Urinary Tract Symptoms
Sites: Glenview, Illinois
Portsmouth Hospitals NHS TrustGovernment (non-federal)
NCT03983707 · 379 participants · Start Jan 23, 2019 · Primary completion Oct 31, 2021
Device: Purastat® · For: Gastrointestinal Bleeding; Delayed Bleeding
Sites: Portsmouth, United Kingdom
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PuraStat", and for the whole product code for context.
This brand
3 reports: 3 malfunction, 0 injury, 0 death
Whole product code QAU
1,141 reports: 957 malfunction, 175 injury, 9 death
Newest reports for this brand
- PURASTATMalfunction
3015528146-2026-00001 · Received Jul 14, 2026 · Event dated Aug 15, 2025
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- PURASTATMalfunction
3012263097-2025-00001 · Received Nov 14, 2025 · Event dated Aug 15, 2025
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- PURASTATMalfunction
22814265 · Received Aug 15, 2025 · Event dated Aug 7, 2025
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Device problem as coded: Therapeutic or Diagnostic Output Failure
Patient problem as coded: Inadequate Pain Relief
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "PuraStat"[tiab]. The summary above synthesizes these.
- PuraStat in gastrointestinal bleeding: results of a prospective multicentre observational pilot study.
Branchi F, Klingenberg-Noftz R, Friedrich K, et al. · Surg Endosc · 2022Multicenter Study, Observational Study
- Efficacy of PuraStat hemostatic gel for pulsating arterial bleeding during colorectal endoscopic submucosal dissection.
Okumura T, Imai K, Hotta K · Dig Endosc · 2023
- Hemostasis: Role of PuraStat® in the prevention and management of gastrointestinal bleeding.
Azer SA · World J Gastrointest Endosc · 2025Editorial
- PuraStat RADA16 Self-Assembling Peptide Reduces Postoperative Abdominal Adhesion Formation in a Rabbit Cecal Sidewall Injury Model.
Gil ES, Aleksi E, Spirio L · Front Bioeng Biotechnol · 2021
- Purastat post-EMR: unresolved questions from the PURPLE trial.
Bhandari P, de Sire R, Repici A · Gut · 2025Letter
- Endoscopic Application of Purastat® in the Treatment of Solitary Rectal Ulcer Syndrome.
Gagliardi M, Sica M, Oliviero G, et al. · J Gastrointestin Liver Dis · 2021
- PuraStat as secondary therapy for hemostasis in Mallory-Weiss syndrome with oral antithrombotic medication.
Higashino M, Murakami H, Hirata T, et al. · DEN Open · 2025
- The Use of PuraStat® in the Management of Walled-Off Pancreatic Necrosis Drained Using Lumen-Apposing Metal Stents: A Case Series.
Binda C, Fugazza A, Fabbri S, et al. · Medicina (Kaunas) · 2023Multicenter Study
- Topical hemostatic agents in endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review.
Gralnek IM, Bhandari P, Alkandari A, et al. · Endoscopy · 2025Systematic Review
- Comparison of PuraStat self-assembling peptide hydrogel versus mineral-based Hemospray for endoscopic hemostasis of upper and lower gastrointestinal lesions in pigs.
Gil ES, O'Neill K, Aleksi E, et al. · Front Gastroenterol (Lausanne) · 2022
- PuraStat for gastrointestinal bleeding management: Effective approach for endoscopic prevention and rescue therapy.
Merola E, Pes GM, Dore MP · Endosc Int Open · 2025Comment
- Efficacy and applications for PuraStat® use in the management of unselected gastrointestinal bleeding: A retrospective observational study.
Ballester R, Costigan C, O'Sullivan AM, et al. · World J Gastrointest Endosc · 2025
Other devices of this type
Also filed under product code QAU.
- Hemospray Endoscopic Hemostat (HEMO-[X])Wilson-Cook Medical, Inc. · De Novo 2026
- NexpowderNextbiomedical Co., Ltd. · 510(k) 2024
- PuraStat GI3-D Matrix, Inc. · 510(k) 2026
- Resolv Endoscopic Hemostat SystemHemostasis, LLC · 510(k) 2024
- PuraStat3-D Matrix, Inc. · 510(k) 2023
- PuraStat-GI3-D Matrix, Inc. · 510(k) 2021
- EndoClotEndoclot Plus Co., Ltd. · 510(k) 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.